RXDX-106 (CEP-40783)

Cat# C5057– 5、25 mg/ bulk size

Storage under -20°C for 3 years / -80°C for 2 years in solvent

INTFORMATION

Product Name	RXDX-106 (CEP-40783)
Cat NO.	C5057
Size	5、25 mg/ bulk size
Description	RXDX-106 (CEP-40783) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/MET inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.
Cas No.	1437321-24-8
Purity	≥ 99%
Molecular Formulation	$C_{31}H_{26}F_2N_4O_6$
Molecular Weight	588.56
In vitro	RXDX-106 inhibits TAM and c-MET phosphorylation in vitro. This inhibition of TAM and c-MET activation in vitro is accompanied by a decrease in downstream MAPK and PI3K signaling and cell viability[1]. It completely inhibits cellular proliferation and viability at sub-nanomolar concentrations in TAM-expressing cells[2].
In vivo	RXDX-106 could inhibit tumors harboring activating TAM gene fusions and affect the TAM-expressing tumor microenvironment to result in a global anti-cancer environment[1].
Solubility (25°C)	DMSO : 10 mg/mL Ethanol : 2 mg/mL Water : Insoluble ♦ <1 mg/ml means slightly soluble or insoluble. ♦ Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Image	 Molecular Weight(MW): 588.56

PREPARING STOCK SOLUTIONS

Volume / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.6991 mL	8.4953 mL	16.9906 mL
5 mM	0.3398 mL	1.6991 mL	3.3981 mL
10 mM	0.1699 mL	0.8495 mL	1.6991 mL
50 mM	-	-	-

PROTOCOL (Only for Reference)

Cell Assay: [2]

Cell lines	3T3 cells
Concentrations	0.25, 1, 2.5, 10, 25, 100, 250 nM
Incubation Time	30 min
Method	3T3 cells expressing Tyro3, Axl, or Mer are incubated with vehicle alone or RXDX- for 30 minutes, and receptor phosphorylation is monitored.

Animal Study: [2]

Animal Models	SCID Beige mice
Dosages	30 mg/kg
Administration	p.o.

Reference

[1] Erin D. Lew, et al. AACR; Cancer Res 2017, 77(13 Suppl):Abstract nr 4191.

[2] Erin D. Lew, et al. EORTC-NCI-AACR. 2016, Abstract #65.

PRODUCT USE LIMITATION

These products are intended for research use only.